TABLE 3.
Effects of 2 months consumption of Allium and placebo on anthropometric indices and biochemical variables in obese women.
| Variables | Allium (n = 16) |
Placebo (n = 16) |
P-value | ||
| Baseline | After intervention | Baseline | After intervention | ||
| Anthropometrics | |||||
| Weight (kg) | 91.0 ± 18.25 | 88.5 ± 21.25* | 88.5 ± 9.38 | 84.5 ± 7.5* | 0.21 |
| BMI (kg/m2) | 35.16 ± 6.96 | 34.20 ± 9.71* | 32.46 ± 3.89 | 31.04 ± 3.13* | 0.46 |
| Waist (cm) | 106.0 ± 11.5 | 98.5 ± 16.0* | 100.0 ± 7.75 | 95.0 ± 7.0* | 0.55 |
| Hip (cm) | 122.0 ± 14.5 | 117.0 ± 16.25* | 115.0 ± 9.75 | 110.0 ± 6.5* | 0.37 |
| WHR | 0.89 ± 0.07 | 0.87 ± 0.05 | 0.86 ± 0.09 | 0.84 ± 0.08 | 0.54 |
| WHtR | 0.66 ± 0.07 | 0.61 ± 0.09* | 0.61 ± 0.03 | 0.58 ± 0.03* | 0.47 |
| Glucose metabolism | |||||
| FBS (mg/dL) | 78.0 ± 13.0 | 78.0 ± 11.0 | 79.0 ± 16.5 | 85.0 ± 9.5 | 0.99 |
| Insulin (mU/L) | 6.7 ± 12.9 | 4.2 ± 4.6* | 7.2 ± 11.2 | 4.8 ± 4.1* | 0.84 |
| HOMA-IR | 1.33 ± 2.63 | 0.95 ± 0.9* | 1.33 ± 1.93 | 1.0 ± 1.2 | 0.58 |
| Lipid profile | |||||
| TC (mg/dL) | 178.0 ± 36.5 | 175.0 ± 41.0 | 182.5 ± 46.25 | 170.5 ± 33.0 | 0.08 |
| TG (mg/dL) | 134.0 ± 93.0 | 127.0 ± 116.0 | 148.0 ± 59.0 | 149.0 ± 80.25 | 0.49 |
| LDL (mg/dL) | 111.0 ± 45.0 | 105.0 ± 33.5 | 114.0 ± 33.5 | 103.0 ± 29.5 | 0.06 |
| HDL (mg/dL) | 37.0 ± 10.0 | 41.0 ± 15.5 | 42.0 ± 11.5 | 41.5 ± 8.75 | 0.84 |
| Liver markers | |||||
| ALT (U/L) | 11.0 ± 5.0 | 12.0 ± 6.0 | 10.0 ± 2.0 | 11.5 ± 7.75 | 0.96 |
| AST (U/L) | 19.0 ± 5.0 | 19.0 ± 4.0 | 19.0 ± 3.75 | 18.5 ± 5.75 | 0.15 |
| Satiety hormone | |||||
| GLP1 (pg/mL) | 29.0 ± 12.0 | 43.2 ± 284.3 | 29.1 ± 16.2 | 86.5 ± 294.53* | 0.36 |
| Inflammatory marker | |||||
| hsCRP (mg/L) | 7.2 ± 5.45 | 5.1 ± 5.2 | 2.0 ± 2.83 | 2.4 ± 8.45 | 0.33 |
| Adipose factors | |||||
| FIAF (ng/mL) | 65.0 ± 37.5 | 60.0 ± 32.5 | 70.0 ± 23.5 | 67.5 ± 13.75 | 0.84 |
| LPL (pg/mL) | 491.7 ± 148.75 | 297.5 ± 1085.55 | 426 ± 208.1 | 494.75 ± 1396.23 | 0.58 |
Data are presented as median ± IQR.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FBS, fasting blood sugar; FIAF, fasting-induced adipose factor; GLP-1, glucagon-like peptide 1; HDL, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high sensitive C reactive protein; LDL, low density lipoprotein cholesterol; LPL, lipoprotein lipase; TC, total cholesterol; TG, triglycerides; WHR, waist to hip ratio; WHtR, waist to height ratio.
*Significant difference within groups.
P-value indicates significance of comparison between groups.